Recent studies have shown that GLP-1 receptors are present in areas of the brain associated with pain processing, leading researchers to investigate the potential analgesic properties of GLP-1 receptor agonists like Semaglutide
Among patients with T2D who had no prior history of CUD, semaglutide was associated with a significantly lower risk for incident CUD diagnosis compared with non-GLP-1RA anti-diabetes medications for a 12-month follow-up period (0.21% vs
Additionally, GLP-1RAs appear to mitigate neuroinflammatory responses by reducing the release of proinflammatory cytokines, such as IL-1, IL-6, and TNF-, while promoting anti-inflammatory mediators [73, 74]
An individual must be within a specific BMI range to meet the guidelines to be prescribed GLP-1s and take part in CAPS medical weight loss program
Most peptides studied show similar safety profiles in men and women